Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.8
Journals
Current Oncology
Special Issues
Renal Cell Carcinoma Management
share announcement

Renal Cell Carcinoma Management

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Genitourinary Oncology".

Deadline for manuscript submissions: closed (15 December 2024) | Viewed by 15880

Special Issue Editor

Dr. Mimma Rizzo

E-Mail
Guest Editor
Division of Medical Oncology, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy
Interests: genitourinary neoplasms; cytotoxic chemotherapy; targeted therapies; immunotherapy; clinical trials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Renal cell carcinoma (RCC) is a commonly diagnosed urological neoplasm with increasing incidence rate. The prognosis of patients with advanced RCC is relatively poor, and around 10% of patients are alive 5 years after diagnosis. The therapeutic landscape of advanced RCC has evolved rapidly in recent years. The major classes of targeted therapies for RCC include: tyrosine-kinase inhibitors of vascular endothelial growth factor receptor (VEGFR), monoclonal antibodies against vascular endothelial growth factor (VEGF), inhibitors of the mammalian target of rapamycin (mTOR) and immune checkpoint inhibitors (ICI). There are several clinical trials ongoing with novel agents and drug combinations to further expand the therapeutic horizon of RCC.

This Special Issue aims to describe the current and future diagnostic-therapeutic management of RCC. In the current challenging therapeutic scenario, the accurate histological, genomic and molecular characterization of the individual tumour and the validation of robust prognostic and predictive biomarkers are needed. Personalised multidisciplinary diagnostic and therapeutic approaches are required to manage RCC patients especially subpopulations that are underrepresented in registrational clinical trials. Moreover, the increasing number of long-term responders to new systemic treatments requires early identification and appropriate management of known and emerging toxicities.

I invite you and your colleagues to submit original research articles or reviews focusing on:

  • histological, genomic and molecular characterization
  • identification of prognostic and predictive biomarkers
  • current status and future directions of systemic therapy
  • management of treatment-related adverse events

I look forward to receiving your contributions.

Dr. Mimma Rizzo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • renal cell carcinoma
  • immunotherapy
  • targeted therapies
  • radiotherapy
  • histopatological characteristics
  • genomic profiling
  • molecular characterization
  • biomarker
  • metabolism
  • adverse events

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 666 KiB  
Article
Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
by Ilya Tsimafeyeu, Vyacheslav Chubenko, Olga Baklanova, Alexey Kalpinskiy, Sufia Safina, Andrei Lebedinets, Vladislav Petkau, Elvira Parsadanova, Maria Turganova, Aleksei Shkurat, Natalia Tovbik, Elena Tkacheva, Yulia Anzhiganova, Olga Novikova, Varvara Bragina, Ruslan Zukov and Rashida Orlova
Curr. Oncol. 2025, 32(1), 11; https://doi.org/10.3390/curroncol32010011 - 27 Dec 2024
Cited by 1 | Viewed by 9354
Abstract
Background: The RAVE-Renal study was conducted to evaluate the real-world efficacy and safety of avelumab plus axitinib as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC). Methods: RAVE-Renal was a multicenter, noninterventional, ambispective study with both retrospective and prospective components. [...] Read more.
Background: The RAVE-Renal study was conducted to evaluate the real-world efficacy and safety of avelumab plus axitinib as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC). Methods: RAVE-Renal was a multicenter, noninterventional, ambispective study with both retrospective and prospective components. The study included adult patients with histologically confirmed mRCC, measurable disease per RECIST version 1.1, and no prior systemic therapy. Patients received avelumab (800 mg intravenously every 2 weeks) plus axitinib (5 mg orally twice daily). The primary endpoints were median progression-free survival (PFS) and objective response rate (ORR). The secondary endpoints included median OS, 1-year overall survival (OS) rate, and safety. Results: A total of 125 patients from 13 sites were enrolled, with a median follow-up of 16.1 months. The median age was 61.0 years. The study population comprised 35.3% favorable, 49% intermediate, and 15.7% poor IMDC risk patients. The median PFS was 14.9 months (95% CI, 11.72–19.08). The ORR was 44.3% (95% CI, 32.5–56.1). The clinical benefit rate was 93.4%. The 1-year OS rate was 71.2%, with the median OS not reached. Any-grade treatment-related adverse events (TRAEs) occurred in 99 (79.2%) cases, including grade ≥3 TRAEs in 24 (19.2%). Conclusions: Avelumab in combination with axitinib showed clinical benefits in a real-world setting, consistent with findings from a pivotal trial. The regimen was effective and well tolerated across various patient subgroups. Full article
(This article belongs to the Special Issue Renal Cell Carcinoma Management)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 340 KiB  
Review
Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma
by Rohit K. Raj, Rituraj Upadhyay, Shang-Jui Wang, Eric A. Singer and Shawn Dason
Curr. Oncol. 2023, 30(12), 10283-10298; https://doi.org/10.3390/curroncol30120749 - 1 Dec 2023
Cited by 3 | Viewed by 2372
Abstract
Stereotactic ablative radiotherapy (SABR) has challenged the conventional wisdom surrounding the radioresistance of renal cell carcinoma (RCC). In the past decade, there has been a significant accumulation of clinical data to support the safety and efficacy of SABR in RCC. Herein, we review [...] Read more.
Stereotactic ablative radiotherapy (SABR) has challenged the conventional wisdom surrounding the radioresistance of renal cell carcinoma (RCC). In the past decade, there has been a significant accumulation of clinical data to support the safety and efficacy of SABR in RCC. Herein, we review the use of SABR across the spectrum of RCC. We performed an online search of the Pubmed database from January 1990 through April 2023. Studies of SABR/stereotactic radiosurgery targeting primary, extracranial, and intracranial metastatic RCC were included. For SABR in non-metastatic RCC, this includes its use in small renal masses, larger renal masses, and inferior vena cava tumor thrombi. In the metastatic setting, SABR can be used at diagnosis, for oligometastatic and oligoprogressive disease, and for symptomatic reasons. Notably, SABR can be used for both the primary renal tumor and metastasis-directed therapy. Management of RCC is evolving rapidly, and the role that SABR will have in this landscape is being assessed in a number of ongoing prospective clinical trials. The objective of this narrative review is to summarize the evidence corroborating the use of SABR in RCC. Full article
(This article belongs to the Special Issue Renal Cell Carcinoma Management)
15 pages, 1284 KiB  
Review
Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma
by Gaetano Pezzicoli, Federica Ciciriello, Vittoria Musci, Francesco Salonne, Anna Ragno and Mimma Rizzo
Curr. Oncol. 2023, 30(10), 9276-9290; https://doi.org/10.3390/curroncol30100670 - 20 Oct 2023
Cited by 8 | Viewed by 3273
Abstract
Clear cell renal cell carcinoma (ccRCC) treatment has undergone three major paradigm shifts in recent years, first with the introduction of molecular targeted therapies, then with immune checkpoint inhibitors, and, more recently, with immune-based combinations. However, to date, molecular predictors of response to [...] Read more.
Clear cell renal cell carcinoma (ccRCC) treatment has undergone three major paradigm shifts in recent years, first with the introduction of molecular targeted therapies, then with immune checkpoint inhibitors, and, more recently, with immune-based combinations. However, to date, molecular predictors of response to targeted agents have not been identified for ccRCC. The WHO 2022 classification of renal neoplasms introduced the molecularly defined RCC class, which is a first step in the direction of a better molecular profiling of RCC. We reviewed the literature data on known genomic alterations of clinical interest in ccRCC, discussing their prognostic and predictive role. In particular, we explored the role of VHL, mTOR, chromatin modulators, DNA repair genes, cyclin-dependent kinases, and tumor mutation burden. RCC is a tumor whose pivotal genomic alterations have pleiotropic effects, and the interplay of these effects determines the tumor phenotype and its clinical behavior. Therefore, it is difficult to find a single genomic predictive factor, but it is more likely to identify a signature of gene alterations that could impact prognosis and response to specific treatment. To accomplish this task, the interpolation of large amounts of clinical and genomic data is needed. Nevertheless, genomic profiling has the potential to change real-world clinical practice settings. Full article
(This article belongs to the Special Issue Renal Cell Carcinoma Management)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop